Approaching tumour therapy beyond platinum drugs : status of the art and perspectives of ruthenium drug candidates.

Abstract : The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with some success the clinical evaluations of phase I and preliminary phase II trials in patients. Here we highlight the strategies that have led to the discovery of metal-based (NAMI-A and KP1019) and of organometallic (RM175, RAPTA-T, RDC11 and DW1/2) ruthenium-based complexes, and we report their main biological/pharmacological characteristics and expectations for further development.
Document type :
Journal articles
Complete list of metadatas

Cited literature [80 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02360300
Contributor : Christian Gaiddon <>
Submitted on : Tuesday, November 12, 2019 - 5:22:30 PM
Last modification on : Wednesday, November 13, 2019 - 1:05:21 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

A. Bergamo, C. Gaiddon, J.H.M. Schellens, J.H. Beijnen, G. Sava. Approaching tumour therapy beyond platinum drugs : status of the art and perspectives of ruthenium drug candidates.. Journal of Inorganic Biochemistry, Elsevier, 2012, 106 (1), pp.90-99. ⟨10.1016/j.jinorgbio.2011.09.030⟩. ⟨inserm-02360300⟩

Share

Metrics

Record views

89